These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 28013405

  • 1. Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial.
    Chandramohan V, Pegram CN, Piao H, Szafranski SE, Kuan CT, Pastan IH, Bigner DD.
    Appl Microbiol Biotechnol; 2017 Apr; 101(7):2747-2766. PubMed ID: 28013405
    [Abstract] [Full Text] [Related]

  • 2. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy.
    Chandramohan V, Bao X, Keir ST, Pegram CN, Szafranski SE, Piao H, Wikstrand CJ, McLendon RE, Kuan CT, Pastan IH, Bigner DD.
    Clin Cancer Res; 2013 Sep 01; 19(17):4717-27. PubMed ID: 23857604
    [Abstract] [Full Text] [Related]

  • 3. EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery.
    Bao X, Pastan I, Bigner DD, Chandramohan V.
    Receptors Clin Investig; 2016 Sep 01; 3(4):. PubMed ID: 28286803
    [Abstract] [Full Text] [Related]

  • 4. Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats.
    Bao X, Chandramohan V, Reynolds RP, Norton JN, Wetsel WC, Rodriguiz RM, Aryal DK, McLendon RE, Levin ED, Petry NA, Zalutsky MR, Burnett BK, Kuan CT, Pastan IH, Bigner DD.
    Invest New Drugs; 2016 Apr 01; 34(2):149-58. PubMed ID: 26728879
    [Abstract] [Full Text] [Related]

  • 5. Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations.
    Chandramohan V, Bao X, Yu X, Parker S, McDowall C, Yu YR, Healy P, Desjardins A, Gunn MD, Gromeier M, Nair SK, Pastan IH, Bigner DD.
    J Immunother Cancer; 2019 May 29; 7(1):142. PubMed ID: 31142380
    [Abstract] [Full Text] [Related]

  • 6. Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors.
    Chandramohan V, Bao X, Kato Kaneko M, Kato Y, Keir ST, Szafranski SE, Kuan CT, Pastan IH, Bigner DD.
    Int J Cancer; 2013 May 15; 132(10):2339-48. PubMed ID: 23115013
    [Abstract] [Full Text] [Related]

  • 7. Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models.
    Parker S, McDowall C, Sanchez-Perez L, Osorio C, Duncker PC, Briley A, Swartz AM, Herndon JE, Yu YA, McLendon RE, Tedder TF, Desjardins A, Ashley DM, Gunn MD, Enterline DS, Knorr DA, Pastan IH, Nair SK, Bigner DD, Chandramohan V.
    Sci Transl Med; 2023 Feb 08; 15(682):eabn5649. PubMed ID: 36753564
    [Abstract] [Full Text] [Related]

  • 8. Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.
    Zalutsky MR, Boskovitz A, Kuan CT, Pegram CN, Ayriss J, Wikstrand CJ, Buckley AF, Lipp ES, Herndon JE, McLendon RE, Bigner DD.
    Nucl Med Biol; 2012 Jan 08; 39(1):23-34. PubMed ID: 21958852
    [Abstract] [Full Text] [Related]

  • 9. Preparation and characterization of fusion protein truncated Pseudomonas Exotoxin A (PE38KDEL) in Escherichia coli.
    Song S, Xue J, Fan K, Kou G, Zhou Q, Wang H, Guo Y.
    Protein Expr Purif; 2005 Nov 08; 44(1):52-7. PubMed ID: 15922623
    [Abstract] [Full Text] [Related]

  • 10. Expression, purification, and characterization of an immunotoxin containing a humanized anti-CD25 single-chain fragment variable antibody fused to a modified truncated Pseudomonas exotoxin A.
    Wang H, Dai J, Li B, Fan K, Peng L, Zhang D, Cao Z, Qian W, Wang H, Zhao J, Guo Y.
    Protein Expr Purif; 2008 Mar 08; 58(1):140-7. PubMed ID: 17950620
    [Abstract] [Full Text] [Related]

  • 11. Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.
    Bruell D, Bruns CJ, Yezhelyev M, Huhn M, Müller J, Ischenko I, Fischer R, Finnern R, Jauch KW, Barth S.
    Int J Mol Med; 2005 Feb 08; 15(2):305-13. PubMed ID: 15647848
    [Abstract] [Full Text] [Related]

  • 12. [Studies of the expression, purification, renaturation and biologic activity of an anti-CEA immunotoxin].
    Yang H, He D, Chao K, Lin Q, You S, Huang HL.
    Sheng Wu Gong Cheng Xue Bao; 2004 May 08; 20(3):348-51. PubMed ID: 15971603
    [Abstract] [Full Text] [Related]

  • 13. Construction, expression, and characterization of an anti-tumor immunotoxin containing the human anti-c-Met single-chain antibody and PE38KDEL.
    Liu Z, Feng Z, Zhu X, Xu W, Zhu J, Zhang X, Fan Z, Ji G.
    Immunol Lett; 2013 Jan 08; 149(1-2):30-40. PubMed ID: 23026237
    [Abstract] [Full Text] [Related]

  • 14. Anti-tumor activity of an immunotoxin (TGFα-PE38) delivered by attenuated Salmonella typhimurium.
    Lim D, Kim KS, Kim H, Ko KC, Song JJ, Choi JH, Shin M, Min JJ, Jeong JH, Choy HE.
    Oncotarget; 2017 Jun 06; 8(23):37550-37560. PubMed ID: 28473665
    [Abstract] [Full Text] [Related]

  • 15. Affinity purification and characterization of anti-Tac(Fv)-C3-PE38KDEL: A highly potent cytotoxic agent specific to cells bearing IL-2 receptors.
    Spence C, Nachman M, Gately MK, Kreitman RJ, Pastan I, Bailon P.
    Bioconjug Chem; 1993 Jun 06; 4(1):63-8. PubMed ID: 8431514
    [Abstract] [Full Text] [Related]

  • 16. Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion.
    Park S, Nguyen MQ, Ta HKK, Nguyen MT, Lee G, Kim CJ, Jang YJ, Choe H.
    Int J Mol Sci; 2021 Jun 17; 22(12):. PubMed ID: 34204265
    [Abstract] [Full Text] [Related]

  • 17. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin.
    Reiter Y, Kreitman RJ, Brinkmann U, Pastan I.
    Int J Cancer; 1994 Jul 01; 58(1):142-9. PubMed ID: 8014011
    [Abstract] [Full Text] [Related]

  • 18. A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma.
    Chandramohan V, Bigner DD.
    Oncoimmunology; 2013 Dec 01; 2(12):e26852. PubMed ID: 24498557
    [Abstract] [Full Text] [Related]

  • 19. Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1.
    Archer GE, Sampson JH, Lorimer IA, McLendon RE, Kuan CT, Friedman AH, Friedman HS, Pastan IH, Bigner DD.
    Clin Cancer Res; 1999 Sep 01; 5(9):2646-52. PubMed ID: 10499644
    [Abstract] [Full Text] [Related]

  • 20. Generation of Potent Anti-HER1/2 Immunotoxins by Protein Ligation Using Split Inteins.
    Pirzer T, Becher KS, Rieker M, Meckel T, Mootz HD, Kolmar H.
    ACS Chem Biol; 2018 Aug 17; 13(8):2058-2066. PubMed ID: 29920062
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.